

Specialists in Surgery

Patient Name	: Mr. Vipin Bhatt	Age/Gender	: 51 Y/M
UHID/MR No.	: STAR.0000060396	OP Visit No	: STAROPV65995
Sample Collected on	:	Reported on	: 29-12-2023 11:32
LRN#	: RAD2194881	Specimen	:
Ref Doctor	: SELF		
Emp/Auth/TPA ID	: 9930934641		

DEPARTMENT OF RADIOLOGY

ULTRASOUND - WHOLE ABDOMEN

LIVER : The liver is normal in size but shows mild diffuse increased echotexture suggestive
of fatty infiltration (Grade I). No focal mass lesion is seen. The intrahepatic biliary tree
& venous radicles appear normal. The portal vein and CBD appear normal.
GALL :The gall bladder is well distended and reveals normal wall thickness. There is no
BLADDER evidence of calculus seen in it.
PANCREAS : The pancreas is normal in size and echotexture. No focal mass lesion is seen.
SPLEEN : The spleen is normal in size and echotexture. No focal parenchymal mass lesion
is seen. The splenic vein is normal.
KIDNEYS : The RIGHT KIDNEY measures 9.8 x 4.1 cms and the LEFT KIDNEY measures
10.0x 4.9 cms in size. Both kidneys are normal in size, shape and echotexture. There
is no evidence of hydroneprosis or calculi seen on either side.
The para-aortic & iliac fossa regions appears normal. There is no free fluid or any
lymphadenopathy seen in the abdomen.
PROSTATE : The prostate measures 3.4 x 2.8 x 2.3 cms and weighs 11.7 gms. It is normal in size,
shape and echotexture. No prostatic calcification is seen.
shape and concretence i no prostance caterneanon is seen.
URINARY : The urinary bladder is well distended and is normal in shape and contour.
BLADDER No intrinsic lesion or calculus is seen in it. The bladder wall is normal in thickness.
DEADDER To multisle lesion of calculus is seen in it. The oradder wan is normal in the kness.
IMPRESSION: The Ultrasound examination reveals mild fatty infiltration of the Liver. No other significant abnormality is detected.

Report with compliments.

winder

Dr. VINOD SHETTY Radiology



Specialists in Surgery

Patient Name	: Mr. Vipin Bhatt	Age/Gender	: 51 Y/M
UHID/MR No.	: STAR.0000060396	OP Visit No	: STAROPV65995
Sample Collected on	:	Reported on	: 29-12-2023 11:44
LRN#	: RAD2194881	Specimen	:
Ref Doctor	: SELF		
Emp/Auth/TPA ID	: 9930934641		

DEPARTMENT OF RADIOLOGY

X-RAY CHEST PA

Both lung fields and hila are normal.

No obvious active pleuro-parenchymal lesion seen .

Both costophrenic and cardiophrenic angles are clear.

Both diaphragms are normal in position and contour.

Thoracic wall and soft tissues appear normal.

CONCLUSION :

No obvious abnormality seen

walk

Dr. VINOD SHETTY Radiology





29/12/2023 OUT-PATIENT RECORD

Date MRNO Name Age/Gender Mobile No Passport No Aadhar number :

60396 mar vipio Bhatt-5140 Imole

Pulse :	B.P: 140/90	Resp: 22/min	Temp: 🔊
Weight:	Height: 162 CM	BMI: 25+7	Waist Circum : 82 CM

General Examination / Allergies History

Clinical Diagnosis & Management Plan

Married, Vegetarian Sleep: @ BBB NO Allerg No eidd ctoon PH: Morten: HeT. Ensen: Desophagear cancerexposed ULA 7-30 DArcid High podrien diet a) Rypeat UA afluis Doorevichs. Physically fit Dr. (Mrs.) CHHAYA P. VAJA M.D. (MUM) Physician & Cardiologist Reg. No. 56942 Doctor Signa Follow up date: TARDE Apollo Spectra Hospitals: 156, Famous Cine Labs, Behind Everest Building, Tardeo, Mumbai - 400 Ph No: 022 - 4332 4500 | www.apollospectra.com

Apollo Specialty Hospitals Pvt. Ltd. (CIN - U85100TG2009PTC099414) (Formerly known as Nova Specialty Hospital Pvt. Ltd.)

Regd. Office: 7-1-617/A, 615 & 616, Imperial Towers, 7th Floor, Ameerpet, Hyderabad, Telangana - 500038 Ph No: 040 - 4904 7777 | www.apollohl.com





ТС	Patient ^N Name ^{V E S}	: Mr.VIPIN BHATT	Collected	: 29/Dec/2023 09:03AM Expertise. Empowering	y
	Age/Gender	: 51 Y 2 M 3 D/M	Received	: 29/Dec/2023 11:03AM	
	UHID/MR No	: STAR.0000060396	Reported	: 29/Dec/2023 02:57PM	
	Visit ID	: STAROPV65995	Status	: Final Report	
	Ref Doctor	: Dr.SELF	Sponsor Name	: ARCOFEMI HEALTHCARE LIMITED	
	Emp/Auth/TPA ID	: 9930934641			

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324

PERIPHERAL SMEAR , WHOLE BLOOD EDTA

Methodology : Microscopic RBC : Normocytic normochromic WBC : Normal in number, morphology and distribution. No abnormal cells seen Platelets : Adequate in Number Parasites : No Haemoparasites seen IMPRESSION : Normocytic normochromic blood picture Note/Comment : Please Correlate clinically

Page 1 of 14



SIN No:BED230325302





		DEPARTMEN	T OF HAEMATOLOG	Y	
	Emp/Auth/TPA ID	: 9930934641	the state of the s		
	Ref Doctor	: Dr.SELF	Sponsor Name	: ARCOFEMI HEALTHCARE	LIMITED
	Visit ID	: STAROPV65995	Status	: Final Report	
	UHID/MR No	: STAR.0000060396	Reported	: 29/Dec/2023 02:57PM	
	Age/Gender	: 51 Y 2 M 3 D/M	Received	: 29/Dec/2023 11:03AM	
то	Patient Name	: Mr.VIPIN BHATT	Collected	: 29/Dec/2023 09:03AM	Expertise. Empowering y

	DEL ARTIMENT OF	TIALMATOLO	01	
ARCOFEMI - MEDIWHEEL - FU	JLL BODY ANNUAL P	LUS ABOVE 50	OY MALE - TMT - PAN IND	A - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

HEMOGRAM, WHOLE BLOOD EDTA

HAEMOGLOBIN	17	g/dL	13-17	CYANIDE FREE COLOUROMETER
PCV .	51.40	%	40-50	PULSE HEIGHT AVERAGE
RBC COUNT	5.72	Million/cu.mm	4.5-5.5	Electrical Impedence
MCV	90	fL	83-101	Calculated
MCH	29.8	pg	27-32	Calculated
MCHC	33.1	g/dL	31.5-34.5	Calculated
R.D.W	12.5	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	9,020	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (DLC)			
NEUTROPHILS	65	%	40-80	Electrical Impedance
LYMPHOCYTES	25	%	20-40	Electrical Impedance
EOSINOPHILS	02	%	1-6	Electrical Impedance
MONOCYTES	08	%	2-10	Electrical Impedance
BASOPHILS	00	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	5863	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	2255	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	180.4	Cells/cu.mm	20-500	Calculated
MONOCYTES	721.6	Cells/cu.mm	200-1000	Calculated
PLATELET COUNT	431000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOPY
ERYTHROCYTE SEDIMENTATION RATE (ESR)	05	mm at the end of 1 hour	0-15	Modified Westergren
PERIPHERAL SMEAR				
Methodology : Microscopic				an fan were it men en annen annen er an er a

RBC : Normocytic normochromic

WBC : Normal in number, morphology and distribution. No abnormal cells seen

Platelets : Adequate in Number

Parasites : No Haemoparasites seen

IMPRESSION : Normocytic normochromic blood picture

Note/Comment : Please Correlate clinically

Page 2 of 14



SIN No:BED230325302





Patient Name ^{VES}	: Mr.VIPIN BHATT		Collected	: 29/Dec/2023 09:03AM	Expertise. Empowering
Age/Gender	: 51 Y 2 M 3 D/M		Received	: 29/Dec/2023 11:03AM	
UHID/MR No	: STAR.0000060396		Reported	: 29/Dec/2023 02:57PM	
Visit ID	: STAROPV65995		Status	: Final Report	
Ref Doctor	: Dr.SELF		Sponsor Name	: ARCOFEMI HEALTHC	ARE LIMITED
Emp/Auth/TPA ID	: 9930934641				
		DEPARTMENT OF	F HAEMATOLOG	Y	
ARCOFI	EMI - MEDIWHEEL - FULL	BODY ANNUAL F	LUS ABOVE 50	MALE - TMT - PAN IN	IDIA - FY2324
Те	est Name	Result	Unit	Bio. Ref. Range	Method
BLOOD GROUP	ABO AND RH FACTOR , 1	VHOLE BLOOD EDT	Ā		
BLOOD GROUP	' TYPE	0			Forward & Reverse Grouping with Slide/Tube Aggluti
Rh TYPE		POSITIVE			Forward & Reverse Grouping with Slide/Tube Agglutination

Page 3 of 14



SIN No:BED230325302





Age/Gender : 51 Y 2 M 3 D/M Received : 29/Dec/2023 10:58AM UHID/MR No : STAR.0000060396 Reported : 29/Dec/2023 11:42AM Visit ID : STAROPV65995 Status : Final Report Ref Doctor : Dr.SELF Sponsor Name : ARCOFEMI HEALTHCARE LIMITED Emp/Auth/TPA ID : 9930934641 DEPARTMENT OF BIOCHEMISTRY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Meth GLUCOSE, FASTING , NAF PLASMA 102 mg/dL 70-100 GOD - POD Comment:	e. Empowerii
Visit ID : STAROPV65995 Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9930934641 DEPARTMENT OF BIOCHEMISTRY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324 Test Name Result Model GLUCOSE, FASTING , NAF PLASMA Arcofemit As per American Diabetes Guidelines, 2023 Fasting Glucose Values in mg/dL Interpretation 70-100 mg/dL Normal 100-125 mg/dL Prediabetes ≥126 mg/dL Diabetes <0 mg/dL Hypoglycemia Note: 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on occasions.	
Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 9930934641 DEPARTMENT OF BIOCHEMISTRY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Meth GLUCOSE, FASTING , NAF PLASMA 102 mg/dL 70-100 GOD - POD Comment: As per American Diabetes Guidelines, 2023 Fasting Glucose Values in mg/dL Interpretation 100-125 mg/dL 0 abetes 2126 mg/dL Prediabetes 2126 mg/dL Diabetes 2126 mg/dL 0 armal Note: I.The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on occasions.	
Emp/Auth/TPA ID : 9930934641 DEPARTMENT OF BIOCHEMISTRY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Meth GLUCOSE, FASTING , NAF PLASMA 102 mg/dL 70-100 GOD - POD Comment: As per American Diabetes Guidelines, 2023 Fasting Glucose Values in mg/dL Interpretation 70-100 mg/dL Normal Diabetes 2126 mg/dL Prediabetes Diabetes >126 mg/dL Diabetes 70 mg/dL Note: I.The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on occasions.	
DEPARTMENT OF BIOCHEMISTRY DEPARTMENT OF BIOCHEMISTRY ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Meth GLUCOSE, FASTING , NAF PLASMA 102 mg/dL 70-100 GOD - POD Comment: As per American Diabetes Guidelines, 2023 Interpretation 70-100 GOD - POD Pasting Glucose Values in mg/dL Interpretation Prediabetes 2126 mg/dL Diabetes >126 mg/dL Diabetes Unibetes Unibetes 100-125 mg/dL 10-125 mg/dL 10-125 mg/dL <th></th>	
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS ABOVE 50Y MALE - TMT - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Meth GLUCOSE, FASTING , NAF PLASMA 102 mg/dL 70-100 GOD - POD Comment: As per American Diabetes Guidelines, 2023 Interpretation Normal Interpretation 70-100 mg/dL Normal Normal Interpretation Interpretation	
Test NameResultUnitBio. Ref. RangeMethGLUCOSE, FASTING , NAF PLASMA102mg/dL70-100GOD - PODComment: As per American Diabetes Guidelines, 2023Fasting Glucose Values in mg/dLInterpretation70-100 mg/dLNormal100-125 mg/dLPrediabetes>126 mg/dLDiabetes<70 mg/dL	
GLUCOSE, FASTING , NAF PLASMA 102 mg/dL 70-100 GOD - POD Comment: As per American Diabetes Guidelines, 2023 Interpretation 70-100 GOD - POD Fasting Glucose Values in mg/dL Interpretation 70-100 GOD - POD 70-100 mg/dL Normal 100-125 mg/dL Prediabetes ≥126 mg/dL Diabetes 2126 mg/dL Diabetes <70 mg/dL Hypoglycemia Note: 1.The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on occasions.	4
Comment: As per American Diabetes Guidelines, 2023 Fasting Glucose Values in mg/dL Interpretation 70-100 mg/dL Normal 100-125 mg/dL Prediabetes ≥126 mg/dL Diabetes <70 mg/dL	nod
Comment: As per American Diabetes Guidelines, 2023 Fasting Glucose Values in mg/dL Interpretation 70-100 mg/dL Normal 100-125 mg/dL Prediabetes ≥126 mg/dL Diabetes <70 mg/dL Hypoglycemia Note: 1.The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on occasions.	
As per American Diabetes Guidelines, 2023 Fasting Glucose Values in mg/dL Interpretation 70-100 mg/dL Normal 100-125 mg/dL Prediabetes ≥126 mg/dL Diabetes <70 mg/dL)
70-100 mg/dL Normal 100-125 mg/dL Prediabetes ≥126 mg/dL Diabetes <70 mg/dL Hypoglycemia Note: 1.The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on occasions.	
100-125 mg/dL Prediabetes ≥126 mg/dL Diabetes <70 mg/dL	
≥126 mg/dL ≥126 mg/dL Ziabetes Ziabetes Ziabetes Ziabetes Ziabetes Ziabetes Ziabetes Hypoglycemia Note: 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on occasions.	
Hypoglycemia Note: I. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on occasions.	
Note: 1. The diagnosis of Diabetes requires a fasting plasma glucose of $>$ or $= 126$ mg/dL and/or a random / 2 hr post glucose value of $>$ or $= 200$ mg/dL on occasions.	
1. The diagnosis of Diabetes requires a fasting plasma glucose of $>$ or $= 126 \text{ mg/dL}$ and/or a random / 2 hr post glucose value of $>$ or $= 200 \text{ mg/dL}$ on occasions.	
occasions.	
	at least 2
2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.	

Page 4 of 14



SIN No:PLF02082086





prostation resources and account of a	Restance of the substance of the second state of the second state of the second state of the second state of the	Constraints of the second s	carego protected and the reason and the reasonable			
○ Patient Name VES	: Mr.VIPIN BHATT		Collected	: 29/Dec/2023 01:04PM	Expertise.	Empowe
Age/Gender	: 51 Y 2 M 3 D/M		Received	: 29/Dec/2023 01:42PM		
UHID/MR No	: STAR.0000060396		Reported	: 29/Dec/2023 01:51PM		
Visit ID	: STAROPV65995		Status	: Final Report		
Ref Doctor	: Dr.SELF		Sponsor Name	: ARCOFEMI HEALTHCA	RE LIMITED	
Emp/Auth/TPA ID	: 9930934641					
	The second seco	DEPARTMENT	OF BIOCHEMISTR	Y		
ARCOFE	EMI - MEDIWHEEL - FUL	L BODY ANNUAL	PLUS ABOVE 50	MALE - TMT - PAN INC	DIA - FY2324	l
Te	est Name	Result	Unit	Bio. Ref. Range	Meth	od

GLUCOSE, POST PRANDIAL (PP), 2 HOURS , SODIUM FLUORIDE PLASMA (2	114	mg/dL	70-140	GOD - POD
HR)				

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 5 of 14



SIN No:PLP1404012





	and the second		and the second sec		IAGINUSI
Patient Name ^{V E S}	: Mr.VIPIN BHATT		Collected	: 29/Dec/2023 09:03AM	Expertise. Empowe
Age/Gender	: 51 Y 2 M 3 D/M		Received	: 29/Dec/2023 04:15PM	
JHID/MR No	: STAR.0000060396		Reported	: 29/Dec/2023 05:26PM	
/isit ID	: STAROPV65995		Status	: Final Report	
Ref Doctor	: Dr.SELF		Sponsor Name	: ARCOFEMI HEALTHCA	RE LIMITED
Emp/Auth/TPA ID	: 9930934641				
			OF BIOCHEMISTR		
	II - MEDIWHEEL - FULL		PLUS ABOVE 501		DIA - FY2324
Tes	t Name	Result	Unit	Bio. Ref. Range	Method
BA1C (GLYCATE	D HEMOGLOBIN), WHO	LE BLOOD EDTA	en en la secontra de la companya da seconda de la companya de la companya de la companya de la companya de la c		
HBA1C, GLYCATE		5.7	%		HPLC
ESTIMATED AVER	RAGE GLUCOSE (eAG)	117	mg/dL		Calculated
PREDIABETES DIABETES DIABETICS	1999 - 1989 - 1985 - 1985 - 1985 - 1985 - 1985 - 1985 - 1985 - 1985 - 1985 - 1985 - 1985 - 1985 - 1985 - 1985 - 1999 - 1996 - 1996 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 -	$5.7 - 6.4$ ≥ 6.5			
EXCELLENT CONTRO	OI.	6 - 7		-	
FAIR TO GOOD CON	NUMBER OF THE OWNER OWN	7-8	inin 11 million and an air air an air an	-	
UNSATISFACTORY (CONTROL	8-10	Birman adal ake raffe kepis kerda antike birkhin orang miladari ya	-	
POOR CONTROL		>10		~	
. HbA1C is recommend Control by American Dia 2. Trends in HbA1C valu 3. Low HbA1C in Non-I s advised in interpretation	below 4%) may be observed in	23. mic control than a sing with Anemia (Iron De patients with clinica	gle test. ficiency/Hemolytic), Live	er Disorders, Chronic Kidney E n erythrocyte life span or decr	

Page 6 of 14



SIN No:EDT230120612





то	Patient Name ^{v ∈ s}	: Mr.VIPIN BHATT	Collected	: 29/Dec/2023 09:03AM Expertise. Empowering
	Age/Gender	: 51 Y 2 M 3 D/M	Received	: 29/Dec/2023 10:58AM
	UHID/MR No	: STAR.0000060396	Reported	: 29/Dec/2023 01:01PM
	Visit ID	: STAROPV65995	Status	: Final Report
	Ref Doctor	: Dr.SELF	Sponsor Name	: ARCOFEMI HEALTHCARE LIMITED
	Emp/Auth/TPA ID	: 9930934641	A	

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - F	ULL BODY	ANNUAL	PLUS ABOV	E 50Y MALE	E - TMT	- PAN IND	IA - FY2324
and a second							
77 (b)							13770 3 2000 VA

Test Name Result Unit Bio. Ref. Range Method

LIPID PROFILE, SERUM

TOTAL CHOLESTEROL	146	mg/dL	<200	CHE/CHO/POD
TRIGLYCERIDES	47	mg/dL	<150	
HDL CHOLESTEROL	56	mg/dL	>40	CHE/CHO/POD
NON-HDL CHOLESTEROL	90	mg/dL	<130	Calculated
LDL CHOLESTEROL	80.6	mg/dL	<100	Calculated
VLDL CHOLESTEROL	9.4	mg/dL	<30	Calculated
CHOL / HDL RATIO	2.61		0-4.97	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

1. Measurements in the same patient on different days can show physiological and analytical variations.

2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.

3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.

4. Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.

5. As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.

Page 7 of 14







ТО	Patleht Name VES	: Mr.VIPIN BHATT	Collected	: 29/Dec/2023 09:03AM Expertise.	Empowering y
	Age/Gender	: 51 Y 2 M 3 D/M	Received	: 29/Dec/2023 10:58AM	
	UHID/MR No	: STAR.0000060396	Reported	: 29/Dec/2023 01:02PM	
	Visit ID	: STAROPV65995	Status	: Final Report	
	Ref Doctor	: Dr.SELF	Sponsor Name	: ARCOFEMI HEALTHCARE LIMITED	
	Emp/Auth/TPA ID	: 9930934641			-

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - F	ULL BODY ANNUAL P	LUS ABOVE 50	Y MALE - TMT - PAN IND	A - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

LIVER FUNCTION TEST (LFT), SERUM

BILIRUBIN, TOTAL	0.90	mg/dL	0.1-1.2	Azobilirubin
BILIRUBIN CONJUGATED (DIRECT)	0.20	mg/dL	0.1-0.4	DIAZO DYE
BILIRUBIN (INDIRECT)	0.70	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	24	U/L	4-44	JSCC
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	22.0	U/L	8-38	JSCC
ALKALINE PHOSPHATASE	134.00	U/L	32-111	IFCC
PROTEIN, TOTAL	7.70	g/dL	6.7-8.3	BIURET
ALBUMIN	4.90	g/dL	3.8-5.0	BROMOCRESOL GREEN
GLOBULIN	2.80	g/dL	2.0-3.5	Calculated
A/G RATIO	1.75		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

• AST - Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.

• ALT – Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI.

- Disproportionate increase in AST, ALT compared with ALP.
- · Bilirubin may be elevated.

• AST: ALT (ratio) - In case of hepatocellular injury AST: ALT > 11n Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen

to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

• ALP - Disproportionate increase in ALP compared with AST, ALT.

- · Bilirubin may be elevated.
- ALP elevation also seen in pregnancy, impacted by age and sex.

• To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.

3. Synthetic function impairment:

• Albumin- Liver disease reduces albumin levels.

• Correlation with PT (Prothrombin Time) helps.

Page 8 of 14





	EMI - MEDIWHEEL - FULI est Name	BODY ANNUAL F	PLUS ABOVE 50)	MALE - TMT - PAN IND	IA - FY2324
		DEPARTMENT O	F BIOCHEMISTR	Y	
Emp/Auth/TPA ID	: 9930934641				
Ref Doctor	: Dr.SELF		Sponsor Name	: ARCOFEMI HEALTHCAF	RE LIMITED
Visit ID	: STAROPV65995		Status	: Final Report	
UHID/MR No	: STAR.0000060396		Reported	: 29/Dec/2023 01:02PM	
Age/Gender	: 51 Y 2 M 3 D/M		Received	: 29/Dec/2023 10:58AM	
Patient Name ^{VES}	: Mr.VIPIN BHATT		Collected	: 29/Dec/2023 09:03AM	Expertise. Empower

Page 9 of 14





	DEPA	RTMENT OF BIOCHEMISTR	Y	
Emp/Auth/TPA ID	: 9930934641			
Ref Doctor	: Dr.SELF	Sponsor Name	: ARCOFEMI HEALTHCAR	E LIMITED
Visit ID	: STAROPV65995	Status	: Final Report	
UHID/MR No	: STAR.0000060396	Reported	: 29/Dec/2023 01:01PM	
Age/Gender	: 51 Y 2 M 3 D/M	Received	: 29/Dec/2023 10:58AM	
Patient Name VES	: Mr.VIPIN BHATT	Collected	: 29/Dec/2023 09:03AM	Expertise. Empowering

ARCOFEMI - MEDIWHEEL - FUL	L BODY ANNUAL P	LUS ABOVE 50	Y MALE - TMT - PAN IND	A - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

CREATININE	0.82	mg/dL	0.6-1.1	ENZYMATIC METHOD
UREA	14.60	mg/dL	17-48	Urease
BLOOD UREA NITROGEN	6.8	mg/dL	8.0 - 23.0	Calculated
URIC ACID	7.70	mg/dL	4.0-7.0	URICASE
CALCIUM	9.90	mg/dL	8.4-10.2	CPC
PHOSPHORUS, INORGANIC	3.80	mg/dL	2.6-4.4	PNP-XOD
SODIUM	140	mmol/L	135-145	Direct ISE
POTASSIUM	4.6	mmol/L	3.5-5.1	Direct ISE
CHLORIDE	99	mmol/L	98-107	Direct ISE

Page 10 of 14







GAMMA GLUTAM (GGT) , SERUM	IYL TRANSPEPTIDASE	32.00	U/L	16-73	Glycylglycine Kinetic method
Test Name		Result	Unit	Bio. Ref. Range	Method
ARCOFE	EMI - MEDIWHEEL - FULL E	BODY ANNUAL	PLUS ABOVE 501	MALE - TMT - PAN I	NDIA - FY2324
	[DEPARTMENT	OF BIOCHEMISTR	Y	
Emp/Auth/TPA ID	: 9930934641				
Ref Doctor	: Dr.SELF		Sponsor Name	: ARCOFEMI HEALTHO	CARE LIMITED
Visit ID	: STAROPV65995	Status	: Final Report		
UHID/MR No	: STAR.0000060396	Reported	: 29/Dec/2023 01:02PM		
Age/Gender	: 51 Y 2 M 3 D/M	Received	: 29/Dec/2023 10:58AM		
Patient Name ^{VES}	Gatient Name ^{VES} : Mr.VIPIN BHATT			: 29/Dec/2023 09:03AM	A Expertise. Empowers

Page 11 of 14





				1.94. Sold and the state of the second s			L	
Patient	ame ^{VES}	: Mr.VIPI	N BHA	ГТ		Collected	: 29/Dec/2023 09:03AM	Expertise. Empowe
Age/Gen	der	:51 Y 2 M	13 D/N	Λ		Received	: 29/Dec/2023 10:58AM	
UHID/MF	R No	: STAR.0	00006	0396		Reported	: 29/Dec/2023 01:01PM	1
Visit ID		: STARO	PV659	95		Status	: Final Report	
Ref Doct	or	: Dr.SEL	F			Sponsor Name	: ARCOFEMI HEALTHC	ARE LIMITED
Emp/Auth	h/TPA ID	: 993093	84641	- 2 - to -				
				E	DEPARTMENT	OF IMMUNOLOGY	1	
	ARCOF	EMI - MEC	DIWH	EL - FULL B	ODY ANNUAL	PLUS ABOVE 50)	MALE - TMT - PAN IN	IDIA - FY2324
	Τ	est Name			Result	Unit	Bio. Ref. Range	Method
HYROI	D PROFI	LE TOTAL	. (T3,	T4 , TSH) , SE	RUM	parte a sua como apo constitui o anagonemia espectaria entre a		
TRI-IODOTHYRONINE (T3, TOTAL)			1.52	ng/mL	0.67-1.81	ELFA		
		4, TOTAL)			9.78	µg/dL	4.66-9.32	ELFA
· · · · · · · · · · · · · · · · · · ·	and the second second in the	JLATING F		ONE	1.630	μIU/mL	0.25-5.0	ELFA
(TSH)						pressie	0.20 0.0	
Kindly o	correlate c	clinically.						
Comme					Rio Pof Pon	go for TSH in ull/ml (As non Amorian	
Comme	ent: nant femal	es			Bio Ref Ran Thyroid Ass	ge for TSH in uIU/ml (,	As per American	
Comme	nant femal	es					As per American	
Comme For preg	nant femal ester	les			Thyroid Ass		As per American	
Commo For preg First trim Second tr Third trin	nant femal ester imester nester				Thyroid Ass 0.1 - 2.5 0.2 - 3.0 0.3 - 3.0	ociation)		
Comme For preg First trim Second tr Third trin 1. TSH is	nant femal ester imester nester a glycopro	tein hormone	e secret	ed by the anterio	Thyroid Ass 0.1 - 2.5 0.2 - 3.0 0.3 - 3.0 or pituitary. TSH ac	ociation)	As per American	rohormone T4 (Thyroxine
Commo For preg First trim Second tr Third trin 1. TSH is Increased	nant femal ester imester nester a glycopro blood level	tein hormone of T3 and T4	inhibit	production of TS	Thyroid Ass 0.1 - 2.5 0.2 - 3.0 0.3 - 3.0 or pituitary. TSH ac SH.	ociation) tivates production of T3	(Triiodothyronine) and its p	
Commo For preg First trim Second tr Third trin 1. TSH is Increased 2. TSH is	nant femal ester imester nester a glycopro blood level elevated in	tein hormone of T3 and T4 primary hypo	inhibit othyroi	production of TS dism and will be	Thyroid Ass 0.1 - 2.5 0.2 - 3.0 0.3 - 3.0 or pituitary. TSH ac SH. low in primary hyp	ociation) tivates production of T3		
Comme For preg First trim Second tr Third trin 1. TSH is Increased 2. TSH is referred to	nant femal ester imester a glycopro blood level elevated in o as sub-clin	tein hormone of T3 and T4 primary hypo- nical hypo- or	inhibit othyroi hypert	production of TS dism and will be hyroidism respec	Thyroid Ass 0.1 - 2.5 0.2 - 3.0 0.3 - 3.0 or pituitary. TSH ac SH. low in primary hyp- tively.	ociation) tivates production of T3 erthyroidism. Elevated o	(Triiodothyronine) and its p r low TSH in the context of ne	ormal free thyroxine is ofte
Comme For preg First trim Second tri Third trin 1. TSH is Increased 2. TSH is referred to 3. Both T ⁴ fraction of	nant femal ester imester a glycopro blood level elevated in o as sub-clin 4 & T3 prov circulating	tein hormone of T3 and T4 primary hypo nical hypo- or vides limited o hormone is fr	inhibit othyroi hypert clinical ree and	production of TS dism and will be hyroidism respec information as be biologically active	Thyroid Ass 0.1 - 2.5 0.2 - 3.0 0.3 - 3.0 or pituitary. TSH ac SH. low in primary hyp- tively. oth are highly bounce.	tivates production of T3 erthyroidism. Elevated o d to proteins in circulatio	r low TSH in the context of ne	ormal free thyroxine is ofte hormone. Only a very sma
Commo For preg First trim Second tr Third trin 1. TSH is Increased 2. TSH is referred to 3. Both T ² fraction of 4. Signific	nant femal ester imester a glycopro blood level elevated in o as sub-clin 4 & T3 prov circulating	tein hormone of T3 and T4 primary hypo nical hypo- or vides limited o hormone is fr	inhibit othyroi hypert clinical ree and	production of TS dism and will be hyroidism respec information as be biologically active	Thyroid Ass 0.1 - 2.5 0.2 - 3.0 0.3 - 3.0 or pituitary. TSH ac SH. low in primary hyp- tively. oth are highly bounce.	tivates production of T3 erthyroidism. Elevated o d to proteins in circulatio	(Triiodothyronine) and its p r low TSH in the context of ne	ormal free thyroxine is ofte hormone. Only a very sma
Comme For preg First trim Second tr Third trin 1. TSH is Increased 2. TSH is referred to 3. Both T ⁴ fraction of	nant femal ester imester a glycopro blood level elevated in o as sub-clin 4 & T3 prov circulating	tein hormone of T3 and T4 primary hypo nical hypo- or vides limited o hormone is fr	inhibit othyroi hypert clinical ree and	production of TS dism and will be hyroidism respec information as be biologically active	Thyroid Ass 0.1 - 2.5 0.2 - 3.0 0.3 - 3.0 or pituitary. TSH ac SH. low in primary hyp- tively. oth are highly bounce.	tivates production of T3 erthyroidism. Elevated o d to proteins in circulatio	r low TSH in the context of ne	ormal free thyroxine is ofte hormone. Only a very sma
Commo For preg First trim Second tr Third trin 1. TSH is Increased 2. TSH is referred to 3. Both T ² fraction of 4. Signific	nant femal ester imester a glycopro blood level elevated in a s sub-clir 4 & T3 prov c irculating ant variatio	tein hormone of T3 and T4 primary hypo nical hypo- or vides limited of hormone is fr ns in TSH car	inhibit othyroi hypert clinical ee and n occur	production of TS dism and will be hyroidism respec information as b biologically active with circadian rh Conditions	Thyroid Ass 0.1 - 2.5 0.2 - 3.0 0.3 - 3.0 or pituitary. TSH ac SH. low in primary hyp- tively. oth are highly boun- e. ythm, hormonal stat	tivates production of T3 erthyroidism. Elevated o d to proteins in circulatio	r low TSH in the context of ne on and reflects mostly inactive on, medication & circulating a	ormal free thyroxine is ofte hormone. Only a very sma
Comme For preg First trim Second tri Third trim 1. TSH is Increased 2. TSH is referred to 3. Both T4 fraction of 4. Signific TSH	nant femal ester imester a glycopro blood level elevated in o as sub-clir 4 & T3 prov circulating ant variatio T3	tein hormone of T3 and T4 primary hypo nical hypo- or /ides limited of hormone is fr ns in TSH car T4	hypert clinical ree and n occur FT4	production of TS dism and will be hyroidism respec information as be biologically active with circadian rhy Conditions Primary Hypoth	Thyroid Ass 0.1 - 2.5 0.2 - 3.0 0.3 - 3.0 r pituitary. TSH ac SH. low in primary hyp- tively. oth are highly bounde. ythm, hormonal stat	ociation) tivates production of T3 erthyroidism. Elevated o d to proteins in circulatio us, stress, sleep deprivatio rroidectomy, Chronic Au	r low TSH in the context of ne on and reflects mostly inactive on, medication & circulating a	ormal free thyroxine is ofte hormone. Only a very smal ntibodies.
Commo For preg First trim Second tr Third trim 1. TSH is Increased 2. TSH is referred to 3. Both T ² fraction of 4. Signific TSH High	nant femal ester imester a glycopro blood level elevated in o as sub-clift 4 & T3 prov circulating ant variatio T3 Low	tein hormone of T3 and T4 primary hypo- nical hypo- or vides limited of hormone is fr ns in TSH car T4 Low	inhibit othyroid hypert clinical ree and h occur FT4 Low	production of TS dism and will be hyroidism respec information as be biologically active with circadian rhy Conditions Primary Hypoth Subclinical Hyp Therapy.	Thyroid Ass 0.1 - 2.5 0.2 - 3.0 0.3 - 3.0 r pituitary. TSH ac SH. low in primary hyp- tively. oth are highly bounde. ythm, hormonal stat	tivates production of T3 erthyroidism. Elevated o d to proteins in circulatio us, stress, sleep deprivatio vroidectomy, Chronic Au mmune Thyroiditis, Insu	r low TSH in the context of no on and reflects mostly inactive on, medication & circulating a	ormal free thyroxine is ofte hormone. Only a very sma ntibodies.
Comme For preg First trim Second tr Third trin 1. TSH is Increased 2. TSH is referred to 3. Both T ² fraction of 4. Signific TSH High	nant femal ester imester a glycopro blood level elevated in o as sub-clir 4 & T3 prov circulating ant variatio T3 Low N	tein hormone of T3 and T4 primary hype nical hypo- or vides limited of hormone is fr ns in TSH car T4 Low N	inhibit othyroid hypert clinical ree and n occur FT4 Low	production of TS dism and will be hyroidism respec information as be biologically active with circadian rh Conditions Primary Hypoth Subclinical Hyp Therapy. Secondary and	Thyroid Ass 0.1 - 2.5 0.2 - 3.0 0.3 - 3.0 or pituitary. TSH ac SH. low in primary hyp- tively. oth are highly bounce. ythm, hormonal stat hyroidism, Post Thy pothyroidism, Autoi Tertiary Hypothyro	tivates production of T3 erthyroidism. Elevated o d to proteins in circulatio us, stress, sleep deprivatio vroidectomy, Chronic Au mmune Thyroiditis, Insu	(Triiodothyronine) and its p r low TSH in the context of no on and reflects mostly inactive on, medication & circulating a itoimmune Thyroiditis fficient Hormone Replacemen	ormal free thyroxine is ofte hormone. Only a very sma ntibodies.
Comme For preg First trim Second tri Third trim 1. TSH is Increased 2. TSH is referred to 3. Both T4 fraction of 4. Signific TSH High High N/Low	nant femal ester imester a glycopro blood level elevated in o as sub-clir 4 & T3 prov ceirculating ant variatio T3 Low N Low	tein hormone of T3 and T4 primary hypo nical hypo- or /ides limited o hormone is fr ns in TSH car T4 Low N Low High	inhibit othyroid hypert clinical ee and n occur FT4 Low N Low	production of TS dism and will be hyroidism respec information as be biologically active with circadian rh Conditions Primary Hypoth Subclinical Hyp Therapy. Secondary and	Thyroid Ass 0.1 - 2.5 0.2 - 3.0 0.3 - 3.0 or pituitary. TSH ac SH. low in primary hyp tively. oth are highly boun- e. ythm, hormonal stat hyroidism, Post Thy pothyroidism, Autoi Tertiary Hypothyro hyroidism, Goitre, T	ociation) tivates production of T3 erthyroidism. Elevated o d to proteins in circulatio us, stress, sleep deprivati vroidectomy, Chronic Au mmune Thyroiditis, Insu idism	(Triiodothyronine) and its p r low TSH in the context of no on and reflects mostly inactive on, medication & circulating a itoimmune Thyroiditis fficient Hormone Replacemen	ormal free thyroxine is ofte hormone. Only a very sma ntibodies.
Commo For preg First trim Second tri Third trim 1. TSH is Increased 2. TSH is referred to 3. Both T ² fraction of 4. Signific TSH High High N/Low Low	nant femal ester imester a glycopro blood level elevated in o as sub-clin 4 & T3 prov circulating ant variatio T3 Low N Low High	tein hormone of T3 and T4 primary hypo nical hypo- or /ides limited o hormone is fr ns in TSH car T4 Low N Low High	inhibit othyroid hypert clinical ree and n occur FT4 Low N Low High	production of TS dism and will be hyroidism respec information as be biologically active with circadian rhy Conditions Primary Hypoth Subclinical Hyp Therapy. Secondary and Primary Hypert Subclinical Hyp	Thyroid Ass 0.1 - 2.5 0.2 - 3.0 0.3 - 3.0 or pituitary. TSH ac SH. low in primary hyp tively. oth are highly boun- e. ythm, hormonal stat hyroidism, Post Thy pothyroidism, Autoi Tertiary Hypothyro hyroidism, Goitre, " perthyroidism	iveriation) tivates production of T3 erthyroidism. Elevated o d to proteins in circulatio us, stress, sleep deprivatio vroidectomy, Chronic Au mmune Thyroiditis, Insui idism Thyroiditis, Drug effects,	G (Triiodothyronine) and its p r low TSH in the context of no on and reflects mostly inactive on, medication & circulating a atoimmune Thyroiditis fficient Hormone Replacemen , Early Pregnancy	ormal free thyroxine is ofte hormone. Only a very smal ntibodies.
Comme For preg First trim Second tri Third trin 1. TSH is Increased 2. TSH is referred to 3. Both T4 fraction of 4. Signific TSH High High N/Low Low	nant femal ester imester a glycopro blood level elevated in o as sub-clir 4 & T3 prov circulating ant variatio T3 Low N Low High N	tein hormone of T3 and T4 primary hypo- nical hypo- or vides limited of hormone is fr ns in TSH car T4 Low N Low High N Low	inhibit othyroio hypert clinical ree and n occur FT4 Low N Low High N Low	production of TS dism and will be hyroidism respec information as be biologically active with circadian rhy Conditions Primary Hypoth Subclinical Hyp Therapy. Secondary and Primary Hypert Subclinical Hyp Central Hypoth	Thyroid Ass 0.1 - 2.5 0.2 - 3.0 0.3 - 3.0 or pituitary. TSH ac SH. low in primary hyperitively. oth are highly bounds. ythm, hormonal statt hyroidism, Post Thypothyroidism, Autoi Tertiary Hypothyro hyroidism, Goitre, Thypothyroidism, Goitre, Thypothyroidism, Goitre, Thypothyroidism, Treatmer	ociation) tivates production of T3 erthyroidism. Elevated o d to proteins in circulatio us, stress, sleep deprivati vroidectomy, Chronic Au mmune Thyroiditis, Insu idism	G (Triiodothyronine) and its p r low TSH in the context of no on and reflects mostly inactive on, medication & circulating a atoimmune Thyroiditis fficient Hormone Replacemen , Early Pregnancy	ormal free thyroxine is ofte hormone. Only a very sma ntibodies.
Comme For preg First trim Second tri Third trim 1. TSH is Increased 2. TSH is referred to 3. Both T4 fraction of 4. Signific TSH High N/Low Low Low	nant femal ester imester a glycopro blood level elevated in o as sub-clir 4 & T3 prov circulating ant variatio T3 Low N Low High N Low	tein hormone of T3 and T4 primary hypo- nical hypo- or vides limited of hormone is fr ns in TSH car T4 Low N Low High N Low	inhibit othyroio hypert clinical ee and n occur FT4 Low N Low High	production of TS dism and will be hyroidism respec information as be biologically active with circadian rhy Conditions Primary Hypoth Subclinical Hyp Therapy. Secondary and Primary Hypert Subclinical Hyp Central Hypoth Thyroiditis, Inte	Thyroid Ass 0.1 - 2.5 0.2 - 3.0 0.3 - 3.0 or pituitary. TSH ac SH. low in primary hyp tively. oth are highly boun- e. ythm, hormonal stat hyroidism, Post Thy pothyroidism, Autoi Tertiary Hypothyro hyroidism, Goitre, " perthyroidism	iveriation) tivates production of T3 erthyroidism. Elevated o d to proteins in circulatio us, stress, sleep deprivatio vroidectomy, Chronic Au mmune Thyroiditis, Insu idism Thyroiditis, Drug effects, nt with Hyperthyroidism	G (Triiodothyronine) and its p r low TSH in the context of no on and reflects mostly inactive on, medication & circulating a atoimmune Thyroiditis fficient Hormone Replacemen , Early Pregnancy	ormal free thyroxine is ofte hormone. Only a very smal ntibodies.

Page 12 of 14



SIN No:SPL23193351





TOTAL PROSTAT (tPSA) , SERUM	TIC SPECIFIC ANTIGEN	0.580	ng/mL	0-4	ELFA		
Test Name		Result	Unit	Bio. Ref. Range	Method		
ARCOF	EMI - MEDIWHEEL - FULL I	BODY ANNUAL	PLUS ABOVE 501	MALE - TMT - PAN I	NDIA - FY2324		
		DEPARTMENT	OF IMMUNOLOGY	Y			
Emp/Auth/TPA ID	: 9930934641						
Ref Doctor	: Dr.SELF		Sponsor Name	: ARCOFEMI HEALTHCARE LIMITED			
Visit ID	: STAROPV65995			: Final Report			
UHID/MR No	: STAR.0000060396		Reported	: 29/Dec/2023 02:38PM			
Age/Gender	: 51 Y 2 M 3 D/M		Received	: 29/Dec/2023 10:58AM			
Patient Name ^{VES}	ame ^{V E S} : Mr.VIPIN BHATT			: 29/Dec/2023 09:03AM	A Expertise. Empowerin		

Page 13 of 14



SIN No:SPL23193351





Emp/Auth/TPA ID	: Dr.SELF : 9930934641	Sponsor Name	: ARCOFEMI HEALTHCARE LIMITED
	: Dr.SELF	Sponsor Name	: ARCOFEMI HEALTHCARE LIMITED
Ref Doctor			
Visit ID	: STAROPV65995	Status	: Final Report
UHID/MR No	: STAR.0000060396	Reported	: 29/Dec/2023 03:19PM
Age/Gender	: 51 Y 2 M 3 D/M	Received	: 29/Dec/2023 01:42PM
Patient Name ^{V E S}	: Mr.VIPIN BHATT	Collected	: 29/Dec/2023 09:03AM Expertise. Empowe

DEPARTMENT	OF	CLINICAL	PATHOLOGY

ARCOFEMI - MEDIWHEEL - FUL	L BODY ANNUAL P	LUS ABOVE 50	Y MALE - TMT - PAN INC	DIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

PHYSICAL EXAMINATION				and a second
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
pН	6.0		5-7.5	Bromothymol Blue
SP. GRAVITY	1.015		1.002-1.030	Dipstick
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE	annan an a	NEGATIVE	PROTEIN ERROR O
GLUCOSE	NEGATIVE		NEGATIVE	GOD-POD
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	NITROPRUSSIDE
UROBILINOGEN	NORMAL	NORMAL		EHRLICH
BLOOD	NEGATIVE		NEGATIVE	Dipstick
NITRITE	NEGATIVE		NEGATIVE	Dipstick
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	PYRROLE HYDROLYSIS
CENTRIFUGED SEDIMENT WET MO	UNT AND MICROSCOPY			
PUS CELLS -	0-1	/hpf	0-5	Microscopy
EPITHELIAL CELLS	0-1	/hpf	<10	MICROSCOPY
RBC	ABSENT	/hpf	0-2	MICROSCOPY
CASTS	NIL		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

*** End Of Report ***

ĺ.

DR. APEKSHA MADAN MBBS, DPB PATHOLOGY

Dr.Sandip Kumar Banerjee M.B.B.S,M.D(PATHOLOGY),D.P.B Consultant Pathologist

Page 14 of 14



SIN No:UR2253303



Patient Name: MR.VIPIN BHATTRef. By: HEALTH CHECK UP

Date : 29-12-2023 Age : 51 years

SONOGRAPHY OF ABDOMEN AND PELVIS

LIVER : The liver is normal in size but shows mild diffuse increased echotexture suggestive of fatty infiltration (Grade I). No focal mass lesion is seen. The intrahepatic biliary tree & venous radicles appear normal. The portal vein and CBD appear normal.

<u>GALL</u> :The gall bladder is well distended and reveals normal wall thickness. There is no evidence of calculus seen in it.

- **PANCREAS** : The pancreas is normal in size and echotexture. No focal mass lesion is seen.
- **SPLEEN** :The spleen is normal in size and echotexture. No focal parenchymal mass lesion is seen. The splenic vein is normal.
- **<u>KIDNEYS</u>** : The **RIGHT KIDNEY** measures 9.8 x 4.1 cms and the **LEFT KIDNEY** measures 10.0x 4.9 cms in size. Both kidneys are normal in size, shape and echotexture. There is no evidence of hydroneprosis or calculi seen on either side.

The para-aortic & iliac fossa regions appears normal. There is no free fluid or any lymphadenopathy seen in the abdomen.

- **PROSTATE**: The prostate measures 3.4 x 2.8 x 2.3cms and weighs 11.7 gms. It is normal in size, shape and echotexture. No prostatic calcification is seen.
- **URINARY** : The urinary bladder is well distended and is normal in shape and contour. **BLADDER** No intrinsic lesion or calculus is seen in it. The bladder wall is normal in thickness.

IMPRESSION: The Ultrasound examination reveals mild fatty infiltration of the Liver. No other significant abnormality is detected.

Report with compliments.

DR.VINOD V.SHETTY

MD, D.M.R.D. CONSAPDIA SPESICNOS POIDLESIEG, Famous Cine Labs, Behind Everest Building, Tardeo, Mumbai - 400034 Ph No: 022 - 4332 4500 | www.apollospectra.com

> Apollo Specialty Hospitals Pvt. Ltd. (CIN - U85100TG2009PTC099414) (Formerly known as Nova Specialty Hospital Pvt. Ltd.) Regd. Office: 7-1-617/A, 615 & 616, Imperial Towers, 7th Floor, Ameerpet, Hyderabad, Telangana - 500038 Ph No: 040 - 4904 7777 | www.apollohl.com



Patient Name	: Mr. Vipin Bhatt	Age	: 51 Y M
UHID	: STAR.0000060396	OP Visit No	: STAROPV65995
Reported on	: 29-12-2023 11:44	Printed on	: 29-12-2023 12:56
Adm/Consult Doctor	:	Ref Doctor	: SELF

DEPARTMENT OF RADIOLOGY

X-RAY CHEST PA

Both lung fields and hila are normal.

No obvious active pleuro-parenchymal lesion seen .

Both costophrenic and cardiophrenic angles are clear.

Both diaphragms are normal in position and contour .

Thoracic wall and soft tissues appear normal.

CONCLUSION :

No obvious abnormality seen

Printed on:29-12-2023 11:44

---End of the Report---

wall

Dr. VINOD SHETTY Radiology

Page 1 of 1

Apollo Spectra Hospitals: 156, Famous Cine Labs, Behind Everest Building, Tardeo, Mumbai - 400034 Ph No:022 - 4332 4500 | www.apollospectra.com

Apollo Specialty Hospitals Pvt. Ltd. (CIN - U85100TG2009PTC099414) (Formerly known as Nova Specialty Hospital Pvt. Ltd.) Regd. Office: 7-1-617/A, 615 & 616, Imperial Towers, 7th Floor, Ameerpet, Hyderabad, Telangana - 500038 Ph No: 040 - 4904 7777 | www.apollohl.com

Name: Mr Vipin Bhatt Age: 51 ye/M - For Health Consultation - Offers no ENT complaints BILTM intact, mobile O/E- Ears J Septim central Muiosa O Nodischorge Nose -Throat - NAD Jup: ENT-NAD MAJ (DR) SHRUTI ANIL SHARMA M.S. (ENT), PGDHHM, PGDMLS MMC - 2019096177

ollo Spec HOSPITAL S Specialists in Surgery

29/12/2023

Apollo Spectra Hospitals: 156, Famous Cine Labs, Behind Everest Building, Tardeo, Mumbai - 400034 Ph No: 022 - 4332 4500 | www.apollospectra.com

Apollo Specialty Hospitals Pvt. Ltd. (CIN - U85100TG2009PTC099414) (Formerly known as Nova Specialty Hospital Pvt. Ltd.) Regd. Office: 7-1-617/A, 615 & 616, Imperial Towers, 7th Floor, Ameerpet, Hyderabad, Telangana - 500038

Ph No: 040 - 4904 7777 | www.apollohl.com

Apollo Spectra HOSPITALS Specialists in Surgery

Date: 29/ 12/2013.

Near Un L.N.6

EYE REPORT

Name: M. Vypin

from Brath

Age /Sex: 517 /M

Complaint:

Are du DOU for distance

Examination

NO MO SELAA

Spectacle Rx

	Right Eye								
	Vision	Sphere	Cyl.	Axis	Vision	Sphere	Cyl.	Axis	
Distance									
Read									

Remarks:

Blow le from

No & wor

Me 6190

•	Trade Name	Frequency	Duration

Follow up:

Funders K www

Consultant:

Apollo Spectra Hospitals Famous Cine Labs, 156, Pt. M. M. Malviya Road, Tardeo, Mumbai - 400 034. Tel.: 022 4332 4500 www.apollospectra.com Ref No.:



DIETARY GUIDELINES FOR BALANCED DIET

Should avoid both fasting and feasting.

-to-

A meal pattern should be followed. Have small frequent and regular meal. Do not exceeds the interval between two meals beyond 3 hours.

Exercise regularly for at least 30-45 minutes daily. Walking briskly is a good form of exercise, yoga, gym, cycling, and swimming.

Keep yourself hydrating by sipping water throughout the day. You can have plain lemon water (without sugar), thin butter milk, vegetable soups, and milk etc.

Fat consumption: - 3 tsp. per day / ½ kg per month per person.

It's a good option to keep changing oils used for cooking to take the benefits of all types of oil.eg: Groundnut oil, mustard oil, olive oil, Sunflower oil, Safflower oil, Sesame oil etc.

FOOD GROUPS	FOOD ITEMS				
Cereals	Whole Wheat and Wheat product like daliya, rava ,bajara, jowar, ragi oats, nachni etc.				
pulses	Dal like moong, masoor, tur and pulses Chana, chhole, rajma , etc.				
Milk	Prefer low fat cow's milk / skim milk and milk product like curd, buttermilk, paneer etc.				
Vegetable	All types of vegetable.				
Fruits	All types of Fruits.				
Nuts	2 Almonds, 2 walnuts, 1 dry anjeer, dates, pumpkin seeds, flax seeds, niger seeds, garden cress seeds.				

FOOD ALLOWED

FOODS TO AVOID

120

Maida and bakery product like Khari, toast, butter, pav, white bread, cake, nankhatai, pastry etc.

Fried sev, fried moong, fried dal, farsan, fafda etc.

Condense milk, concentrated milk sweets, butter, cheese, cream.

Groundnut, Coconut (Dry and fresh), Cashew nut, pista.

Hydrogenated fat like dalda, salted butter, ready to eat items, fast food, processed, preserves and canned food.

Carbonated beverages (soft drink), excess amount of tea and coffee, alcohol.

Papad, pickles, chutney.

Alcohol, smoking and Tabaco should be strictly avoided.

Fauziya Ansari Clinical Nutritionist/ Dietician E: diet.trd@apollospectra.com Cont.: 8452884100



ID	o vipin	B holf Height	162cm	Date	29. 12. 2023	APOLLO SPECTRA HOSPITAL
Age			Male			

Body Composition

	新建度 合		lonnol.			Ove	t		UNIT%	Normal Range
Weight	40 55	70 85	100 11	67.5^{5}	145 kg	160	175	190	205	49. 1 ~ 66. 4
Muscle Mass	60 70	⁸⁰ 90	100 11 () kg	0 120	130	140	150	160	170	24. 5~29. 9
Body Fat Mass		60 80	100 16	0 220	280 100100 2	³⁴⁰ 25. 7	400 kg	460	520	6.9~13.9
T B W Total Body Water	30. 7 kg (3	32. 5~ 39). 7)	F·F / Fat Free				41	L. 8 kg ((42. 1~52. 5)
Protein	8. 3 kg (8	3. 7~10.	6)	Min	iera	*		2.	81 kg ((3. 00~ 3. 67)

* Mineral is estimated.

✓ Deficient

M Deficient

Under

₩ Under

Under

Under

Under 🗆 Under

Extremely Over

Deficient Mexcessive

V Over

□ Strong

V Over

∀ Over

M Over

V Over

56

	Segmen	tal Lean	Evaluation	
	2. 3kg Under		2.4kg Under	
		Trunk		
Left		20.9kg Normal		nigin
	6. 6kg Under		6. 5 kg Under	

Lean Mass

Obesity Diagnosis

Obesity L	Jagnosi	S		Nutrition	al Evaluatio	n
1 - Carlos			Normal Range	Protein	Normal	
BMI	2			Mineral	□ Normal	1
Body Mass Index	(kg/m ²)	25.7	18. $5 \sim 25.0$	Fat	□ Normal	
				Weight M	lanagemen	t
PBF Percent Body Fat	(%)	38.0	10.0~20.0	Weight	Normal	1
Percent body rat				SMM	□ Normal	1
WHR		1 00	0.00.00	Fat	□ Normal	[
Waist-Hip Ratio		1.02	0.80~0.90	Obesity D	Diagnosis	
0.440				BMI	Normal	-
B M R Basal Metabolic Ra	(kcal)	1274	$1485 \sim 1733$	PBF	□Normal	
				WHR	Normal	[

PBF Fat Mass Segmental Fat Evaluation 42.4% 40.6% 1. 8kg 1.8kg Over Over Trunk 38.6% Righ 13.9kg ef Over 33.5% 33.9% 3. 5kg 3.5kg Over Over

* Segmantal Fat is estimated.

Impedance

Z	RA	LA	TR	RL	LL
20kHz	361.6	383.7	31.3	328.4	317.7
100kHz	319.6	338.9	26.4	294.4	287.3

Muscle-Fat Control

Muscle Control 7.2 kg Fat Control **Fitness Score** - 17. 0 kg

* Use your results as reference when consulting with your physician or fitness trainer.

Exercise Planner Plan your weekly exercises from the followings and estimate your weight loss from those activities.

Energy	expend	iture of e	each activ	vity(base	weight:	67. 5 kg	/ Durati	ion:30m	in./ unit:	kcal)		0
0,777	Walking 135	B	Jogging 236	15	Bicycle 203	a	Swim 236	Śv	Mountain Climbing 220	Y	Aerobic 236	1
Rio	Table tennis 153	Rio	Tennis	R'	Football 236	C.S.	Oriental Fencing 338	R	Gate ball	(C) 1	Badminton	4
1º	Racket ball 338	-	Tae- kwon-do 338	- 10	Squash 338	Xª.	Basketball	A A	Rope jumping 236	-7	Golf 119	4
and the second	Push-ups development of upper body		Sit-ups abdominai muscle training	Pup	Weight training beckache prevention	K	Dumbibeil exercise musdestrangth	R. C.	Elastic band muscle strangth	- 20 ·	Squats maintenance of lower body muscle	0

How to do


- 1. Choose practicable and preferable activities from the left.
- 2. Choose exercises that you are going to do for 7 days.
- 3. Calculate the total energy expenditure for a week.
- 4. Estimate expected total weight loss for a month using the formula shown below.


Recommended calorie intake per day


iower body muscle	1300	kcal
nerov expen	diture (kcalóweek) X Awa	ooks - 7700


*Calculation for expected total weight loss for 4 weeks: Total energy expenditure (kcal/week) X 4weeks ÷ 7700


Copyright @1996-2006 by Biospace Co., Ltd. All rights reserved. BR-IND-40-A-060721






















Technician:	-1.1	0.2 -0.2		EXERCISE ST 0:00 1	-	29-Dec-2023 12:34:02	BHATT, VIPIN ID: 000060396
	aVF -0.6	aVL 0.0 0.1	aVR -0.3 -0.7	BASELINE STAGE 1 117bpm 1.4METS	Referred by: Test ind:	51years	
APOLIO SPECTRA	V3 1.6 1.2	V2 2.1 1.3	V1 0.1	om ST @ 10mm/mV 80ms postJ		Asian Male	
TARDEO MIIMRAI	V6 0.0 0.6	V5 0.0 0.3	V4 0.7 1.0	Lead ST(mm) Slope(mV/s)		Max BP:	GRADED EXERCISE SUMMARY BRUCE Max HR: 188bpm11
Unconfirmed		0.9 -0.5		EXERCISE STA 2:00 4.6			1% of
	aVF 0.6 -0.2	aVL -0.2 -0.6	aVR -0.5 -1.2	MAX ST STAGE 1 111bpm 4.6METS		Maximum workload:	Total Exercise time: max predicted 169bpm
MAC:55 009C	V3 1.8 1.8	V2 2.5 0.9	V1 -0.5	1 ST @ 10mm/mV 80ms postJ		ad: 7.2METS	
	V6 0.0 -1.8	V5 -2.1 -0.6	V4 0.6 1.7	Lead ST(mm) Slope(mV/s)		100hz	25.0 mm/s 10.0 mm/mV

Technician:	-1.1		I 0.2 0.5	EXERCISE ST 0:00 1.	BHATT, VIPIN ID: 000060396 29-Dec-2023 12:34:02
	aVF 0.3 -0.6	aVL 0.0 0.1	aVR -0.3 -0.7	Test ind: BASELINE STAGE 1 117bpm 1.4METS	
A POLI LO SDECTERA	V3 1.6 1.2	V2 2.1 1.3	VI 1.1 0.1	ST @ 10mm/mV 80ms postJ	Asian Male
TARDEO MIIMBAI	0.0 0.6	V5 0.0 0.3	V4 V4 1.0	Lead ST(mm) Slope(mV/s)	BRUCE BRUCE Max HR: 188bpm11 Max BP: 150/100 Reason for Termina Comments: STRESS
Unconfirmed	-1.7			M EXERCISE STAGE 1 2:00 4.6METS	BRUCE Total Exercise 1 BRUCE Total Exercise 1 Max HR: 188bpm111% of max predicted 169b Max BP: 150/100 Maximum work Reason for Termination: Target HR Achieved Comments: STRESS TEST IS NEGATIVE.
	aVF 0.6 -0.2	aVL -0.2 -0.6	aVR -0.5 -1.2	MAX ST E 1 111bpm ETS	Total Exercise time: 188bpm111% of max predicted 169bpm 150/100 Maximum workload: r Termination: Target HR Achieved : STRESS TEST IS NEGATIVE.
MACES 000C		V2 2.5 0.9	V1 0.5 -0.5	ST @ 10mm/mV 80ms postJ	: 6:08 : 7.2METS
	-1.8	-2.1 -0.6	V4	Lead ST(mm) Slope(mV/s)	25.0 mm/s 10.0 mm/mV 100hz

			a the many many also and a second						
	146	140/90	104	1.0	***	***	2:13	Post	RECOVERY
	263	150/100	175	7.2	14.0	3.4	0:08	STAGE 3	
	246	150/100	164	7.0	12.0	2.5	3:00	STAGE 2	
			167	4.6	10.0	1.7	3:00	STAGE 1	EXERCISE
			117	1.4	0.0	0.8	1:34	HYPERVENT	
40			87	1.0	**	***	0:16	STANDING	
HANNING -	120	140/90	6	1.0	* .*	•*	25:11	SUPINE	PRETEST
TARDEO.	(x100)	(mmHg)	(bpm)	(METS)	(%)	(mph)	Stage	Name	Name
CLALTY Y	RPP	BP	HR	WorkLoad	Grade	Speed	Time in	Stage	Phase
ardiologist	Physician & Cardiologist Reg. No. 56942	Phy						Test ind:	
Dr. (Mrs.) CHHAYA P. VAJA M D (MUM)	Ars.) CHH	Dr. (N						Roferrad	Pof
			NEGATIVE	Comments: STRESS TEST IS NEGATIVE.	nments: STR	Cor			12:34:02
ZUONT	1.2ME 10	load:	et HR Achieved	ination: Targe	Reason for Termin	Rea	Male	o Lyears Asian	29-Dec-2023
10.0 mm/mV			predicted 1	111% of max	x HR: 188bpr	Ma			ID: 000060396
40.0 IIIII/ S		ise time: 6:08	Total Exercise time:		BRUCE	BR			BHATT, VIEIN